Literature DB >> 10675114

Risks of leukaemia and solid tumours in individuals with Down's syndrome.

H Hasle1, I H Clemmensen, M Mikkelsen.   

Abstract

BACKGROUND: Individuals with Down's syndrome have a greater risk of leukaemia than the general population, but reliable estimates of the age-specific risk are lacking and little is known about the risk of solid tumours.
METHODS: We identified 2814 individuals with Down's syndrome from the Danish Cytogenetic Register, and linked the data to the Danish Cancer Registry. The number of person-years at risk was 48453. Standardised incidence ratio (SIR) and 95% CI were calculated of the basis of cancer rates specific for age and sex in the general population.
FINDINGS: 60 cases of cancer were found, with 49.8 expected (SIR 1.20 [95% CI 0.92-1.55]). Leukaemia constituted 60% of cases of malignant disease overall and 97% of cases in children. The SIR for leukaemia varied with age, being 56 (38-81) at age 0-4 years and 10 (4-20) at 5-29 years. No cases of leukaemia were seen after the age of 29 years. The SIR for acute myeloid leukaemia was 3.8 (1.7-8.4) times higher than that for acute lymphoblastic leukaemia in children aged 0-4 years. The cumulative risk for leukaemia by the age of 5 years was 2.1% and that by 30 years was 2.7%. Only 24 solid tumours were seen, with 47.8 expected (0.50 [0.32-0.75]). No cases of breast cancer were found, with 7.3 expected (p=0.0007). Higher than expected numbers of testicular cancers, ovarian cancers, and retinoblastomas were seen but were not significant. INTREPRETATION: The occurrence of cancer in Down's syndrome is unique with a high risk of leukaemia in children and a decreased risk of solid tumours in all age-groups. The distinctive pattern of malignant diseases may provide clues in the search for leukaemogenic genes and tumour-suppressor genes on chromosome 21.

Entities:  

Mesh:

Year:  2000        PMID: 10675114     DOI: 10.1016/S0140-6736(99)05264-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  197 in total

1.  Breast screening guidelines should be adapted in Down's syndrome.

Authors:  Daniel Satgé; Annie J Sasco
Journal:  BMJ       Date:  2002-05-11

2.  Trisomy-21 gene dosage over-expression of miRNAs results in the haploinsufficiency of specific target proteins.

Authors:  Terry S Elton; Sarah E Sansom; Mickey M Martin
Journal:  RNA Biol       Date:  2010-09-01       Impact factor: 4.652

3.  Health conditions associated with aging and end of life of adults with Down syndrome.

Authors:  Anna J Esbensen
Journal:  Int Rev Res Ment Retard       Date:  2010

4.  DYRK1A overexpression enhances STAT activity and astrogliogenesis in a Down syndrome mouse model.

Authors:  Nobuhiro Kurabayashi; Minh Dang Nguyen; Kamon Sanada
Journal:  EMBO Rep       Date:  2015-09-15       Impact factor: 8.807

5.  Transient myeloproliferative disorder and GATA1 mutation in neonates with and without Down syndrome.

Authors:  Ming-Horng Tsai; Jia-Woei Hou; Chao-Ping Yang; Pong-Hong Yang; Shih-Ming Chu; Jen-Fu Hsu; Ming-Chou Chiang; Hsuan-Rong Huang
Journal:  Indian J Pediatr       Date:  2011-02-02       Impact factor: 1.967

6.  Survival and morbidity outcomes for very low birth weight infants with Down syndrome.

Authors:  Nansi S Boghossian; Nellie I Hansen; Edward F Bell; Barbara J Stoll; Jeffrey C Murray; Abbot R Laptook; Seetha Shankaran; Michele C Walsh; Abhik Das; Rosemary D Higgins
Journal:  Pediatrics       Date:  2010-11-22       Impact factor: 7.124

Review 7.  Malignancy in children with trisomy 21.

Authors:  Karen R Rabin; James A Whitlock
Journal:  Oncologist       Date:  2009-01-28

Review 8.  Constitutional aneuploidy and cancer predisposition.

Authors:  Ithamar Ganmore; Gil Smooha; Shai Izraeli
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

9.  Maternal health conditions during pregnancy and acute leukemia in children with Down syndrome: A Children's Oncology Group study.

Authors:  Simona Ognjanovic; Susan Puumala; Logan G Spector; Franklin O Smith; Leslie L Robison; Andrew F Olshan; Julie A Ross
Journal:  Pediatr Blood Cancer       Date:  2009-05       Impact factor: 3.167

10.  JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome.

Authors:  Kathryn D Tuttle; Katherine A Waugh; Paula Araya; Ross Minter; David J Orlicky; Michael Ludwig; Zdenek Andrysik; Matthew A Burchill; Beth A J Tamburini; Colin Sempeck; Keith Smith; Ross Granrath; Dayna Tracy; Jessica Baxter; Joaquin M Espinosa; Kelly D Sullivan
Journal:  Cell Rep       Date:  2020-11-17       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.